Compare and contrast two antiparasitic agents—fenbendazole and mebendazole—through the lens of integrative oncology. Dr. Nathan Goodyear explores their overlapping and distinct anticancer mechanisms, including microtubule disruption, immune modulation, and impact on tumor metabolism. This module reviews pharmacokinetics, safety data, dosing considerations, and clinical applications of each agent. Designed for practitioners seeking to deepen their understanding of repurposed therapies, this course highlights how each compound may target different hallmarks of cancer and support terrain-based protocols.